Equillium‘s patent involves peptide antagonists targeting ?c-family cytokines associated with diseases like leukemia and autoimmune disorders. The patent claims a nucleotide sequence encoding a composite peptide inhibiting multiple ?c-cytokine family members. This innovation has potential therapeutic and cosmetic applications, as well as research utility. GlobalData’s report on Equillium gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Equillium, Molecular diagnosis biomarkers was a key innovation area identified from patents. Equillium's grant share as of January 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.
Inhibitors of ?c-cytokine activity using peptide antagonists
See Also:
A recently granted patent (Publication Number: US11834519B2) discloses a nucleotide sequence encoding a composite peptide that includes amino acid sequences from at least two interleukin (IL) protein gamma-c-box D-helix regions. The composite peptide is designed to inhibit the activity of multiple ?c-cytokines, such as IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. The patent further details the composition of the peptide conjugate and its pharmaceutical application in treating various ?c-cytokine-mediated diseases, including myasthenia gravis, rheumatoid arthritis, and inflammatory respiratory diseases like asthma and COPD.
Moreover, the patent encompasses methods for blocking signaling by ?c-cytokine family members, inhibiting ?c-cytokine binding to a ?c-subunit, and treating conditions like HTLV-1-associated myelopathy (HAM)/tropical spastic paraparesis (TSP) associated diseases. Additionally, the patent extends to cosmetic applications, offering a method for treating cosmetic conditions like acne, hair loss, and signs of aging. The genetic construct described in the patent includes regulatory elements to control the expression of the composite peptide, which can effectively target and inhibit the activity of multiple ?c-cytokines. This patent showcases innovative approaches in the field of genetic constructs and pharmaceutical compositions for treating a wide range of diseases and conditions associated with ?c-cytokines.
To know more about GlobalData’s detailed insights on Equillium, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
